Zoom Online Lecture: https://tinyurl.com/ye287jrk

Meeting ID: 945 2585 8201

Password: 947480

Abstract:

Many patient-derived tumor models have emerged recently. However, their potential to guide personalized drug selection remains unclear. Here, we report a novel patient-derived tumor- like cell clusters (PTCs) that could accomplish 100-5,000 drug testing within 10 days. Unlike other 3D tumor models, PTCs contain primary tumor epithelium self-assembled with endogenous stromal cells, and show a high degree of similarity to the original tumors in phenotypic and genotypic features. More importantly, PTC drug-testing assays reveal an overall consistency of over 90% in predicting the clinical outcomes. CD8+ T cells assembled in PTCs show the heterogeneity in expansion and cytotoxicity response, and the combination of cell viability and IFN-γ value enables the accurate prediction of clinical outcome of patients treated with the Programmed Cell Death 1 (PD1) antibody therapies. Together, these data indicate that PTC is a promising in vitro preclinical model for personalized medicine and basic research.

Biography:

Dr. Xi received his B.S. degree in Chemical Engineering at Beijing Institute of Technology in 1996,

M.S degree in Cell biology at Tsinghua University in 2000, and Ph.D. degree in Biomedical Engineering at UCLA in 2004. He jointed Peking University since 2005.

Dr. Xi currently serves in five scientific societies, including vice director of Organoid and Organ Chip, and vice director of Diagnosis Branch of China Medicinal Biotech Association and vice director of Gene Diagnosis Branch of China Medicinal Biotech Association. He serves as peer reviewer for Science, JACS and so on. He received “New Century Excellent Talents in University” in 2009.

Dr. Xi’s current research interests include precision oncology, cell microarray, genome editing, or miRNA in cancers. Recently, he developed a new personalized medicine model that facilitate the therapy selection for cancer patients with the accuracy of 90% in predicting the clinical outcomes. Up to now, he already published over 90 peer-reviewed SCI papers in top journals, including Nature, Nature Genetics, Nature Cell Biology, Nature Materials, PNAS, Angew. Chem. Int. Ed., etc.. Dr. Xi have received 17 grants and got a National Key Project entitled “The Development of 3D Stem Cell- Differentiated Organoid Chip and Their Applications” as a Chief Scientist in 2018.

ALL INTERESTED ARE WELCOME